• Explore /
  • Poster
  • / IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.

IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.

Abstract Video & Slides Poster

Authors

Martin Reck

Martin Reck

Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany

Martin Reck , Minu K SRIVASTAVA , Heather A. Wakelee , Enriqueta Felip , Nasser K. Altorki , Tibor Csoszi , Vladimir Moiseyenko , Andrey Akopov , Alexey Smolin , Antonio Chella , Eric Vallieres , Alex Martinez-Marti , Wei Zou , V. McNally , Elizabeth Bennett , Hen Prizant , Barzin Nabet , Marcus Ballinger , Barbara J. Gitlitz , Caicun Zhou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT02486718

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8522)

DOI

10.1200/JCO.2023.41.16_suppl.8522

Abstract #

8522

Poster Bd #

149

Abstract Disclosures

Similar Posters

First Author: Heather A. Wakelee

First Author: Yuming Zhu

First Author: Heather A. Wakelee

First Author: Charu Aggarwal